Concert Pharmaceuticals Inc
NASDAQ:CNCE
Concert Pharmaceuticals Inc
NASDAQ:CNCE
Price:
8.37 USD
Market Closed
Updated:
Jun 2, 2024
Concert Pharmaceuticals Inc
Additional Paid In Capital
|
Concert Pharmaceuticals Inc
Additional Paid In Capital Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Concert Pharmaceuticals Inc
NASDAQ:CNCE
|
Additional Paid In Capital
$461.8m
|
CAGR 3-Years
18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Additional Paid In Capital
$20.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Additional Paid In Capital
$6.8B
|
CAGR 3-Years
19%
|
CAGR 5-Years
22%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Additional Paid In Capital
$7.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Additional Paid In Capital
$11.9B
|
CAGR 3-Years
20%
|
CAGR 5-Years
23%
|
CAGR 10-Years
18%
|
See Also
What is Concert Pharmaceuticals Inc's Additional Paid In Capital?
Additional Paid In Capital
461.8m
USD
461.8m
USD
Based on the financial report for Dec 31, 2021, Concert Pharmaceuticals Inc's Additional Paid In Capital amounts to 461.8m USD.
What is Concert Pharmaceuticals Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
12%
12%
Over the last year, the Additional Paid In Capital growth was 15%. The average annual Additional Paid In Capital growth rates for Concert Pharmaceuticals Inc have been 18% over the past three years , 12% over the past five years .
You don't have any saved screeners yet
